Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Recursion Pharmaceuticals is raising $235,506,731.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christopher Gibson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Recursion Pharmaceuticals

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. .

To learn more about Recursion Pharmaceuticals, visit http://www.recursionpharma.com/

Contact:
Christopher Gibson, Chief Executive Officer
385-269-0203
christopher.gibson@recursionpharma.com
https://www.linkedin.com/in/chris-gibson-5ab66065/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved